NCT02586675: TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer |
|
|
| Completed | 1 | 7 | US | Tamoxifen, Ribociclib, LEE011, Cyclin-Dependent Kinase (CDK) Inhibitor, Goserelin, Zoladex, Goserelin acetate | H. Lee Moffitt Cancer Center and Research Institute, Novartis | Breast Cancer, Breast Cancer - Female, Breast Cancer - Male | 05/17 | 10/21 | | |
